research A case of rosacea fulminans during pregnancy with review of the literature
Pregnancy can trigger severe rosacea, which may be treated with antibiotics and steroids, but there's no clear treatment guideline.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Adverse effect profile with low-dose methotrexate therapy in patients suffering with rheumatic diseases
Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
research P23 A case of visceral leishmaniasis presenting as seropositive erosive rheumatoid arthritis in an immunocompromised patient
Visceral leishmaniasis can mimic rheumatoid arthritis symptoms, especially in immunocompromised patients.
research Phase-specific differential regulation of mechanical allodynia in a murine model of neuropathic pain by progesterone
Progesterone initially worsens but later reduces neuropathic pain in mice, through different mechanisms.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/research/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Late onset leflunomide-induced cutaneous ulcers in a seronegative arthritis patient: A case report
Stopping leflunomide healed the woman's skin ulcers.
research Mechanistic Insights on Dyspepsia Modulation by Salvia rosmarinus Through Network Pharmacology, Molecular Docking, and Molecular Dynamics
Rosemary may help reduce dyspepsia and gastric cancer risk.
research Tooth Development Associated with Mutations in Hereditary Vitamin D–Resistant Rickets
Early detection of specific VDR mutations is crucial for effective treatment and better dental outcomes in children with hereditary vitamin D–resistant rickets.
research Use of Rituximab for Dermatomyositis Over Conventional Therapy: A Case Report
Rituximab improved her dermatomyositis better than usual treatments.
research Hair Growth-promoting Effect of Resina Pini and Its Main Constituent, Abietic Acid, in Mouse Model of Alopecia
Pine resin and abietic acid were found to promote hair growth in mice.
research Ablative Fractional Resurfacing in Topical Drug Delivery: An Update and Outlook
Ablative fractional resurfacing could improve how well topical drugs penetrate the skin, but more research is needed to fine-tune the method.
research Herpes Zoster Precipitating First Attack of Neuromyelitis Optica along with Perinuclear Anti-Neutrophilic Cytoplasmic Antibody Positive Vasculitis
A woman's shingles infection triggered her first episode of a rare neurological disorder and blood vessel inflammation.
research The involvement of the neurosteroid allopregnanolone in the antihyperalgesic effect of paroxetine in a rat model of neuropathic pain
Paroxetine relieves pain by increasing allopregnanolone levels.
research Efficacy of adipose stromal cells-enriched high-density fat graft combined with BTX-A for Raynaud’s phenomenon: a prospective cohort study
Combining fat grafts with botulinum toxin helps improve Raynaud's symptoms.
research Genetic Disorders and Defects in Vitamin D Action
Two rare genetic diseases cause severe rickets in children due to defects in vitamin D metabolism.
research Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems
Reducing reactive oxygen species can help treat nerve damage from platinum cancer drugs.
research TRPV3 as a Therapeutic Target for Itch
Blocking TRPV3 may help treat itch in dry skin conditions.
research Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Ultrastructural aspect of the keratinolytic activity of piedra.
Piedraia hortae fungi dissolve both the outer and inner layers of hair.
research The Comparative Potency of Hydrocortisone Analogs in Suppressing Growth of Hair in the Rat121From the Departments of Dermatology and Syphilology and of Anatomy, University of Michigan Medical School, Ann Arbor, Michigan.2Supported in part by research grants from the National Institutes of Health, United States Public Health Service (A-131 (C5)), the University of Michigan Memorial-Phoenix Project #145 and The Upjohn Company.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Phase separation: a new window in RALF signaling
LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.
research Drug news and therapeutic news
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.